The retina is a thin, light-sensitive layer located at the back of the eye. It contains specialized cells known as rods and cones, which convert light into electrical signals that are sent to the brain for visual processing. Rod cells are responsible for vision in low-light conditions, while cone cells provide daytime and color vision. In dogs affected by PRA (rcd1), these photoreceptor cells develop abnormally and progressively deteriorate over time, leading to irreversible vision impairment.
Clinical signs of PRA (rcd1) often begin at a young age because the disease affects retinal development rather than causing degeneration later in life. One of the earliest symptoms is night blindness, where affected dogs have difficulty seeing in dim lighting or darkness. Owners may notice hesitation when navigating dark rooms, reluctance to go outside at night, or bumping into objects in low-light environments. As the disease progresses, daytime vision also becomes impaired. Affected dogs may struggle to locate toys, navigate unfamiliar surroundings, or avoid obstacles. Eventually, significant visual impairment or complete blindness may occur. Despite the severity of vision loss, PRA (rcd1) is generally not painful, and many dogs adapt well to their environment using their other senses.
The PRA (rcd1) DNA Health Test is designed to identify the specific genetic mutation associated with rod-cone dysplasia type 1. Testing is simple, safe, and non-invasive, typically requiring either a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine the dog's genetic status. Because DNA remains unchanged throughout life, testing can be performed at any age, including in puppies before clinical signs appear.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the PRA (rcd1) mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected by the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing Progressive Retinal Atrophy (rcd1).
Genetic testing for PRA (rcd1) provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that help reduce the prevalence of the disease while preserving healthy genetic diversity within the breed population. Avoiding the mating of two carrier dogs significantly decreases the risk of producing affected puppies.
For dog owners, understanding a dog's genetic status allows for proactive eye health monitoring and regular veterinary ophthalmic examinations. Dogs identified as at risk can benefit from routine retinal evaluations to monitor vision and detect changes as early as possible. While there is currently no cure for PRA (rcd1), early diagnosis can help owners prepare for progressive vision loss and make environmental adjustments that support their dog's safety and quality of life.
The Progressive Retinal Atrophy PRA (rcd1) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine eye health, and helps reduce the impact of this inherited retinal disorder in future generations. Through early detection and informed breeding decisions, breeders and owners can contribute to healthier dogs and improved long-term visual welfare.
